Biogen Inc. (BIIB) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - General secteur d'activité. Le siège social de l'entreprise est situé à Cambridge, MA, United States. Le PDG actuel est Christopher A. Viehbacher.
BIIB a date d'introduction en bourse 1991-09-17, 7,605 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $26.26B.
Biogen Inc. is a global biopharmaceutical company founded in 1978 and headquartered in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for neurological and neurodegenerative diseases. The company maintains a robust portfolio of approved treatments across multiple therapeutic areas, including multiple sclerosis (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, OCREVUS), spinal muscular atrophy (SPINRAZA), Alzheimer's disease (ADUHELM), and oncology and immunology indications (RITUXAN, GAZYVA), alongside a growing biosimilar franchise featuring etanercept, adalimumab, and infliximab biosimilars. Beyond its marketed products, Biogen maintains an extensive pipeline of investigational therapies targeting neurological disorders, including candidates for multiple sclerosis, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease, and immunology-related conditions. The company leverages strategic collaborations with leading pharmaceutical and biotechnology partners including Genentech, Eisai, Ionis Pharmaceuticals, and Sage Therapeutics to advance its research and development initiatives across its core therapeutic focus areas.
